Cargando…

Cardiorenal benefits of finerenone: protecting kidney and heart

Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role...

Descripción completa

Detalles Bibliográficos
Autores principales:	González-Juanatey, José R., Górriz, Jose Luis, Ortiz, Alberto, Valle, Alfonso, Soler, Maria Jose, Facila, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891162/ https://www.ncbi.nlm.nih.gov/pubmed/36719097 http://dx.doi.org/10.1080/07853890.2023.2171110

Ejemplares similares

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
por: Lv, Ruolin, et al.
Publicado: (2023)

Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin
por: Theofilis, Panagiotis, et al.
Publicado: (2022)

Practical approaches to building up a cardiorenal clinic
por: de la Espriella, Rafael, et al.
Publicado: (2022)

Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
por: Piccirillo, Francesco, et al.
Publicado: (2023)

Cardiorenal Fat: A Cardiovascular Risk Factor With Implications in Chronic Kidney Disease
por: D'Marco, Luis, et al.
Publicado: (2021)

Case report: Denosumab-associated acute heart failure in patients with cardiorenal insufficiency
por: Xing, Yuexian, et al.
Publicado: (2022)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
por: Ghosal, Samit, et al.
Publicado: (2023)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Cardiorenal Protection in Diabetic Kidney Disease
por: Lee, Jason F., et al.
Publicado: (2021)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Heart-Kidney Interaction: Epidemiology of Cardiorenal Syndromes
por: Cruz, Dinna N., et al.
Publicado: (2010)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Coronavirus disease 2019 in chronic kidney disease
por: D’Marco, Luis, et al.
Publicado: (2020)

Optimizing the timing of nephrology referral for patients with diabetic kidney disease
por: Martínez-Castelao, Alberto, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes
por: de la Espriella, Rafael, et al.
Publicado: (2020)

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
por: González-Blázquez, Raquel, et al.
Publicado: (2018)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
por: Górriz, José Luis, et al.
Publicado: (2020)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

Finerenone for chronic kidney disease associated with type 2 diabetes with albuminuria
Publicado: (2023)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Cardiorenal syndrome and diabetes: an evil pairing
por: Méndez Fernández, Ana Belén, et al.
Publicado: (2023)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Cardiovascular and Renal Links along the Cardiorenal Continuum
por: García-Donaire, José A., et al.
Publicado: (2011)

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
por: Shaikh, Aisha, et al.
Publicado: (2022)

Multidisciplinary approach to patients with heart failure and kidney disease: preliminary experience of an integrated cardiorenal unit
por: Marques, María, et al.
Publicado: (2023)

Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model
por: Sereno, José, et al.
Publicado: (2012)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s3t1vkeusvggqqkfv9nisets0r